Skip to content

Investigate the protective effects of dexmedetomidine in patients undergoing limb ischemia-reperfusion

Investigate the effects of dexmedetomidine in patients undergoing limb ischemia-reperfusion

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045801
Enrollment
Unknown
Registered
2021-04-25
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

limb ischemia-reperfusion

Interventions

control group:received an equal amount of 0.9% saline
dexmedetomidine group:prior to tourniquet inflation patients received a loading dose of dexmedetomidine (0.8µg/kg over 10 min), followed by continuous infusion of dexmedetomidine (0.5 µg/kg/h)until en

Sponsors

Tianjin Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. ASA grade 1-3, patients (20-75 years old) who undergo elective lower extremity surgery and require tourniquets during the operation; 2. There are no contraindications for intraspinal anesthesia, no chronic bronchitis, asthma, etc. The estimated tourniquet application time is 60-90 minutes.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of arrhythmia and heart failure, with abnormal liver and kidney function; 2. There is a history of hormone application one week before the operation, and the expected anesthesia time is less than 1 hour or more than 4 hours, with signs of acute infection, and a history of immune system, nervous system and mental illness.

Design outcomes

Primary

MeasureTime frame
Tumor necrosis factor-a;Interleukin-6;Brain-derived neurotrophic factor(BDNF);Endothelin-1;Pigment epithelium-derived factor;

Secondary

MeasureTime frame
Nausea, vomiting and other;

Countries

China

Contacts

Public ContactRen Wanlu

Tianjin Hospital

renwanlu@hotmail.com+86 13920993190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026